



**GEOVAX LABS, INC.**

**Condensed Consolidated Statements of Operations Information**  
**(amounts in thousands, except per share data)**

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2019	2018	2019	2018
Grant and collaboration revenue	\$ 333	\$ 349	\$ 907	\$ 664
Operating expenses:				
Research and development	468	557	1,475	1,417
General and administrative	291	459	1,214	1,175
	759	1,016	2,689	2,592
Loss from operations	(426)	(667)	(1,781)	(1,928)
Other income (expense), net	2	-	1	2
Net loss	\$ (424)	\$ (667)	\$ (1,780)	\$ (1,926)
Loss per common share	\$ (0.03)	\$ (1.99)	\$ (0.37)	\$ (6.43)

**Condensed Consolidated Balance Sheet Information**  
**(amounts in thousands)**

	Sep. 30,	Dec. 31,
	2019	2018
Assets:		
Cash and cash equivalents	\$ 569	\$ 260
Other current assets	226	360
Total current assets	795	620
Property, net	10	11
Other assets	11	11
Total assets	\$ 816	\$ 642
Liabilities and stockholders' equity (deficiency)		
Current liabilities	\$ 1,808	\$ 1,624
Note payable, net of current portion	29	40
Stockholders' equity (deficiency)	(1,021)	(1,022)
Total liabilities and stockholders' equity (deficiency)	\$ 816	\$ 642
Common shares outstanding	95,628	438